CDISC Submission Data Standards Team Recognized for Creation of SDTM
Wayne, PA -- May 25, 2005 -- Octagon Research Solutions, the leader in the electronic transformation of clinical R&D, announced today that Tom Guinter, vice president of clinical data strategies, is a recipient of the Food and Drug Administration's (FDA) Leveraging/Collaboration Award. The award recognizes the Clinical Data Interchange Standards Consortium (CDISC) Submission Data Standards (SDS) Team for their work in the creation of the Study Data Tabulation Model (SDTM) and accompanying implementation guide.
The SDS Team was formed to define standard metadata models for case report tabulations and analysis datasets submitted to the FDA that will enable agency reviewers to replicate analyses without requiring complex programming. A secondary objective for the team was to develop metadata model usage documentation for relevant data domains applicable to industry. The Study Data Tabulation Model and accompanying Implementation Guide represent the continuous evolution and practical application of the new standard for submission of clinical data.
Jim Walker, president and CEO, Octagon Research Solutions, commented, "We are very proud of Tom's activities and contributions toward the development of CDISC data standards. We view these evolving submission data standards as enablers to greater change within the industry. Octagon and our leadership team are committed to supporting the development and implementation of such standards in order to gain greater efficiencies in the drug development process."
Tom Guinter noted, "The members of the CDISC SDS team have invested countless hours toward this goal. They leveraged their individual experiences, collaborating on all aspects of this data model without regard to personal or individual company preference. The experience of working with a team of individuals so passionate about the issues and so committed to achieving the team goals is incredibly rewarding in and of itself. We are delighted and honored that the team's efforts and achievements were recognized by the agency for this particular award."
The award will be presented to the SDS team at the Commissioner Honor Awards Ceremony on June 10th in Bethesda, MD.About Octagon Research Solutions, Inc.
Octagon is a leading process-centric solutions provider that offers a suite of regulatory, clinical, process and IT solutions to the life sciences industry. Octagon synchronizes processes and increases automation to reduce island-to-island inefficiencies within the clinical research and development process. We leverage the power of electronic submissions through cross-functional eSub expertise, a holistic process approach, deep domain knowledge and creative use of technology. Octagon is headquartered in Wayne, PA, with offices in Boston, MA and Costa Mesa, CA. For more information please visit www.octagonresearch.com.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.